Alkem ranks among the top five pharmaceutical companies in India, boasting a workforce of over 17,000 employees and a global presence with affiliates in the USA, Australia, UK, Germany, and various other emerging markets. Alkem is a prominent player in the anti-infective market, distinguished by its clinical development expertise and a well-established commercial infrastructure.
Furthermore, Alkem holds 144 Abbreviated New Drug Applications (ANDAs), operates two manufacturing facilities, and has two research and development (R&D) centers in the US market. With its robust clinical development capabilities and access to an extensive clinical network, Alkem is positioned as a formidable corporate partner for Biosergen.
Biosergen AB and Alkem Laboratories Ltd announced their partnership in a co-development and licensing agreement for BSG005, an innovative polyene macrolide. This collaboration aims to advance BSG005 through phase II and phase III clinical trials for eventual distribution in the Indian market.
BSG005, developed by Biosergen AB, targets the treatment of severe and challenging-to-treat invasive fungal diseases. After successful phase I studies, the first patient trial will begin in India, focusing on individuals with severe fungal infections resistant or intolerant to Amphotericin B. India’s high incidence of life-threatening fungal infections underscores the importance of this development.
Alkem will oversee the initial clinical trial, focusing on patients with severe fungal infections such as mucormycosis (Black Fungus), aspergillosis, and candidiasis, who are intolerant or resistant to Amphotericin B. BSG005 has shown promise in preclinical and phase I trials, offering a potential treatment option for these patients. Upon successful trials in India, Biosergen and Alkem plan to expand its use to similar patient groups in the United States and the European Union through pivotal trials. Alkem will invest in the clinical development of BSG005 and receive an exclusive license to market it in India.
Investors should keep a close eye on this trending stock.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.